ReNAgade Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
640 Memorial Dr, Cambridge, Massachusett...Phone Number
(617) 456-8652Website
www.renagadetx.comRevenue
$33.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About ReNAgade Therapeutics
Based in Cambridge, MA, ReNAgade Therapeutics is a biotechnology company with a focus on RNA medicines.Explore more
ReNAgade Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ReNAgade Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on ReNAgade Therapeutics recently announced quarterly report
Check out if ReNAgade Therapeutics is spiking on competitors!
Click to see if ReNAgade Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once ReNAgade Therapeutics has new funding data
Product Launch: Get notified when ReNAgade Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if ReNAgade Therapeutics has recently received funding, and reach out quickly before it becomes old news!
ReNAgade Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at ReNAgade Therapeutics
Recommended Actions
Find VP level buyers at ReNAgade Therapeutics
Find more new buyers
Compare Similar Companies to ReNAgade Therapeutics
Compare insights from companies similar to ReNAgade Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
ReNAgade Therapeutics
$33.8M
51-200
Private
$300M
2021
GS
Gregory SieczkiewiczInterim Chief Legal Officer
Company Profile Activity
Activity Insights
ReNAgade Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ReNAgade Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ReNAgade Therapeutics.
ReNAgade Therapeutics financials insights
Gather financial insights about ReNAgade Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$300M
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Event
Events
ReNAgade Therapeutics News & Media
Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies
Unifies World-Class Validated Circular RNA and Industry-leading Delivery Technologies to Advance New Category of panCAR™ in vivo CAR RNA Medicines for Oncology and Autoimmune Diseases Amit Munshi to Lead Company as Chief Executive Officer Former Orna CEO Tom Barnes, Ph.D., to Remain on...CORRECTING and REPLACING ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions. The updated release reads: RENAGADE THERAPEUTICS CONTINUES COMMITMENT TO GANNA BIO AND GLYCAN BIOLOGY GanNA founders include Carolyn Bertozzi, Ph.D., Richard D. Cummings, Ph.D., Ryan A. Flynn, M.D., Ph.D., and Namita Bisaria, Ph.D., M.B.A. Additional investment strengthens ReNAgade’s delivery platform with unique conjugation platform based on novel gReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland. “We are excited to highlight foundational research and development advancements at ASGCT supported by our poster pres
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding ReNAgade Therapeutics
Sign Up For FreeTo access detailed company insights
Based in Cambridge, MA, ReNAgade Therapeutics is a biotechnology company with a focus on RNA medicines.... Read More
